LifeStance executive granted 179,856 RSUs

LifeStance Health Group executive Ryan McGroarty reported an equity award of company stock.

Accepted by SEC EDGAR 03/09/2026 - 08:07 PM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

LifeStance Health Group executive Ryan McGroarty reported an equity award of company stock. On March 5, 2026, he acquired 179,856 shares of common stock through a grant at a price of $0.00 per share, described as restricted stock units where each unit represents one share of common stock. Following this award, his directly held common stock holdings increased to 727,611 shares, including the newly granted RSUs, which vest into actual shares subject to their terms.

Insider Trade Summary

Grant/Award: 179,856 shares

Grant/Award 1 txn

Insider McGroarty Ryan

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	179,856	$0.00	$0.00

Holdings After Transaction: Common Stock — 727,611 shares (Direct)

Footnotes (1)

F1. Includes 179,856 restricted stock units ("RSUs") granted on March 5, 2026. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LifeStance Health (LFST) report for Ryan McGroarty?

LifeStance Health reported that executive Ryan McGroarty received an equity award of 179,856 shares of common stock on March 5, 2026. The filing classifies this as a grant or award acquisition rather than an open-market stock purchase or sale.

How many LifeStance Health (LFST) shares does Ryan McGroarty hold after this Form 4?

After the March 5, 2026 award, Ryan McGroarty is shown holding 727,611 shares of LifeStance Health common stock directly. This total includes 179,856 restricted stock units, each representing a contingent right to receive one share of common stock in the future.

Was cash paid for the LifeStance Health (LFST) shares granted to Ryan McGroarty?

No cash was paid for the awarded shares; the reported transaction price per share is $0.00. The Form 4 describes the transaction as a grant or award acquisition, meaning the shares were issued as compensation rather than purchased in the open market.

What type of equity did Ryan McGroarty receive from LifeStance Health (LFST)?

Ryan McGroarty received 179,856 restricted stock units, or RSUs, from LifeStance Health. Each RSU represents a contingent right to receive one share of common stock, typically subject to vesting or other conditions defined under the company’s compensation arrangements.

Does the LifeStance Health (LFST) Form 4 show a buy or sell by Ryan McGroarty?

The Form 4 does not show a buy or sell in the market; it reports an acquisition through a grant of 179,856 restricted stock units. This is categorized as a grant, award, or other acquisition, rather than a traditional purchase or sale transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McGroarty Ryan

(Last)

(First)

(Middle)

C/O LIFESTANCE HEALTH GROUP, INC.

4800 N. SCOTTSDALE ROAD, SUITE 2500

(Street)

SCOTTSDALE

85251

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
LifeStance Health Group, Inc. [ LFST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/05/2026		A		179,856⁽¹⁾	A	$0	727,611	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Includes 179,856 restricted stock units ("RSUs") granted on March 5, 2026. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Remarks:

Chief Financial Officer and Treasurer

	By: /s/ Ryan Pardo, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR